NCT05407519View on ClinicalTrials.gov

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Tislelizumab + Sitravatinib

Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI

Trial Locations (1)

230000

RECRUITING

Anhui province hospital, Hefei

All Listed Sponsors
collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

lead

Anhui Provincial Hospital

OTHER_GOV